Europe grants orphan drug status for Amplimexon(R)

AmpliMed Corporation announced that the European Commission has granted an orphan product designation for Amplimed's lead drug, Amplimexon(TM) for the treatment of ovarian cancer.

Amplimexon is currently in clinical trials evaluating safety and efficacy in combination with gemcitabine in patients with malignant melanoma, in combination with Taxotere® for the treatment of lung, breast and prostate cancer and as a monotherapy for the treatment of refractory multiple myeloma.